Implantable zoledronate-PLGA microcapsules ameliorate alveolar bone loss,gingival inflammation and oxidative stress in an experimental periodontitis rat model
Restricted accessResearch articleFirst published online January, 2021
Implantable zoledronate-PLGA microcapsules ameliorate alveolar bone loss,gingival inflammation and oxidative stress in an experimental periodontitis rat model
The effect of implantable Zoledronate-PLGA microcapsules (PLGA-ZOL) in periodontitis remains unclear. In this study, we aimed to explore the potential role of PLGA-ZOL in protecting periodontitis and elucidate the underlying mechanism. A rat model of periodontitis was established by ligation the mandibular first molars, then PLGA-ZOL was implanted. The healing volume was scanned by cone-beam computed tomography. Cytokine levels in the gingival tissues were determined by ELISA and RT-PCR. Oxidative stress was indicated by detecting superoxide dismutase concentration and catalase activity. After periodontitis model was successfully established in rats, PLGA-ZOL treatment significantly attenuated alveolar bone loss, as indicated by the increased total healing volume, bone volume/tissue volume and osteoprotegerin level, as well as decreased sRANKL level. PLGA-ZOL treatment also suppressed the inflammatory activities by inhibiting pro-inflammatory cytokine production (TNF-α, IL-1β) but increasing anti-inflammatory cytokine secretion (IL-10). Furthermore, PLGA-ZOL was found to ameliorate oxidative stress in gingival tissues. In conclusion, PLGA-ZOL microcapsules ameliorate alveolar bone loss, gingival inflammation and oxidative stress in an experimental rat model of periodontitis.
KinaneDFLappinDF.Immune processes in periodontal disease: a review. Ann Periodontol2002;
7: 62–71.
3.
SchwartzZGoultschinJDeanDD, et al.
Mechanisms of alveolar bone destruction in periodontitis. Periodontol 20001997;
14: 158–172.
4.
AralCAAralKYayA, et al.
Effects of colchicine on gingival inflammation, apoptosis, and alveolar bone loss in experimental periodontitis. J Periodontol2018;
89: 577–585.
5.
MaJSorsaTBillinghurstCR, et al.
Direct evidence of collagenolysis in chronic periodontitis. J Periodontal Res2003;
38: 564–567.
6.
DeasDEMealeyBL.Response of chronic and aggressive periodontitis to treatment. Periodontol 20002010;
53: 154–166.
7.
WangTFJenIAChouC, et al.
Effects of periodontal therapy on metabolic control in patients with type 2 diabetes mellitus and periodontal disease: a meta-analysis. Medicine (Baltimore)2014;
93: e292.
8.
NathSGRaveendranR.Microbial dysbiosis in periodontitis. J Indian Soc Periodontol2013;
17: 543–545.
9.
DarveauRP.The oral microbial consortium's interaction with the periodontal innate defense system. DNA Cell Biol2009;
28: 389–395.
10.
RenLLeungWKDarveauRP, et al.
The expression profile of lipopolysaccharide-binding protein, membrane-bound CD14, and toll-like receptors 2 and 4 in chronic periodontitis. J Periodontol2005;
76: 1950–1959.
11.
TonettiMSImbodenMALangNP.Neutrophil migration into the gingival sulcus is associated with transepithelial gradients of interleukin-8 and ICAM-1. J Periodontol1998;
69: 1139–1147.
12.
MoughalNAAdonogianakiEThornhillMH, et al.
Endothelial cell leukocyte adhesion molecule-1 (ELAM-1) and intercellular adhesion molecule-1 (ICAM-1) expression in gingival tissue during health and experimentally-induced gingivitis. J Periodont Res1992;
27: 623–630.
13.
MeuricVLe Gall-DavidSBoyerE, et al.
Signature of microbial dysbiosis in periodontitis. Appl Environ Microbiol2017;
83: 05–10.
14.
MajorPPColemanRE.Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol2001;
28: 17–24.
15.
RosenLSGordonDKaminskiM, et al.
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J2001;
7: 377–387.
16.
ReidIRHorneAMMihovB, et al.
Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med2018;
379: 2407–2416.
17.
EzraAGolombG.Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev2000;
42: 175–195.
18.
HelmiMAlOsaimySGoodsonJM, et al.
Annual alveolar bone loss in older adults taking oral bisphosphonate: a retrospective cohort study. BMC Oral Health2019;
19: 260–211.
19.
LiuHShiSCaoJ, et al.
Preparation and evaluation of a novel bioactive glass/lysozyme/PLGA composite microsphere. Drug Dev Ind Pharm2015;
41: 458–463.
20.
ZhangSLiuJGeB, et al.
Enhanced antitumor activity in A431 cells via encapsulation of 20(R)-ginsenoside Rg3 in PLGA nanoparticles. Drug Dev Ind Pharm2017;
43: 1734–1741.
21.
NaghipoorJRabczukT.A mechanistic model for drug release from PLGA-based drug eluting stent: a computational study. Comput Biol Med2017;
90: 15–22.
22.
SindeevaOAGusliakovaOIInozemtsevaOA, et al.
Effect of a controlled release of epinephrine hydrochloride from PLGA microchamber array: in vivo studies. ACS Appl Mater Interfaces2018;
10: 37855–37864.
23.
DortaMJOlivaAMunguiaO, et al.
In-vitro release of fluoropyrimidines from PLGA film implants. J Pharm Pharmacol2002;
54: 757–763.
24.
MaYSongJAlmassriHNS, et al.
Minocycline-loaded PLGA electrospun membrane prevents alveolar bone loss in experimental peridontitis. Drug Deliv2020;
27: 151–160.
25.
TeixeiraAHFreireJMOde SousaLHT, et al.
Stemodia maritima L. Extract decreases inflammation, oxidative stress, and alveolar bone loss in an experimental periodontitis rat model. Front Physiol2017;
8: 988–912.
26.
HasturkHKantarciA.Activation and resolution of periodontal inflammation and its systemic impact. Periodontol 20002015;
69: 255–273.
27.
StruillouXBoutignyHSoueidanA, et al.
Experimental animal models in periodontology: a review. Open Dent J2010;
4: 37–47.
28.
OzHSPuleoDA.Animal models for periodontal disease. J Biomed Biotechnol2011;
2011: 754857–754802.
29.
NicuEALoosBG.Polymorphonuclear neutrophils in periodontitis and their possible modulation as a therapeutic approach. Periodontol 20002016;
71: 140–163.
30.
YigitUKirziogluFYUguzAC, et al.
Is caffeic acid phenethyl ester more protective than doxycycline in experimental periodontitis?Arch Oral Biol2017;
81: 61–68.
31.
GorskaRGregorekHKowalskiJ, et al.
Relationship between clinical parameters and cytokine profiles in inflamed gingival tissue and serum samples from patients with chronic periodontitis. J Clin Periodontol2003;
30: 1046–1052.
32.
YuYBiCSWuRX, et al.
Effects of short-term inflammatory and/or hypoxic pretreatments on periodontal ligament stem cells: in vitro and in vivo studies. Cell Tissue Res2016;
366: 311–328.
33.
HasturkHKantarciAGoguet-SurmenianE, et al.
Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol2007;
179: 7021–7029.
34.
Gómez-FloritMMonjoMRamisJM.Quercitrin for periodontal regeneration: effects on human gingival fibroblasts and mesenchymal stem cells. Sci Rep2015;
5: 16593–16511.
